EphemerisX Research · Deep research
Cross-investigations whose records belong together as a comparable evidence. How this research works →
AllComparable evidenceDivergent outcomeRegulatory pathwayShared concern
The FDA's letters to Replimune and, by Outlook's account, to Outlook said added analyses did not alter its conclusion. Replimune then went to an advisory committee; Outlook appealed to the Office of New Drugs. Both moved forward on trials already in their applications.
Replimune, Outlook and Aldeyra each received FDA letters on effectiveness. One rested on a single-arm trial, one on a successful trial and a second that missed its endpoint, one on several trials with mixed results.
Aldeyra Therapeutics · Outlook Therapeutics · ReplimuneRead →
Prepared from public FDA letters and SEC filings: every quoted passage is matched to the original document, and every “not in” statement comes from a search of the whole document, before it is published. Questions, summaries and connecting sentences are EphemerisX’s wording. Not investment advice. How this research works → · Ask the FDA and SEC Ephemeris →
